Generic Biologics: 505(b)(2) Route Still Open, But Scientific Issues Unresolved

FDA is declining to rule out the possibility that the Sec. 505(b)(2) process could be used to allow expedited approval of follow-on biologic projects

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet